Safety of risdiplam in spinal muscular atrophy patients after short‐term treatment with nusinersen

Our study showed good safety data on patients who received risdiplam following nusinersen within the washout period of 90 days. This supplements the JEWELFISH study in the era of DMT, providing additional guidance for clinicians, but additional data from other centers is needed.